Cat.No. | Name | Information |
---|---|---|
M53242 | Lys-(Des-Arg9, Leu8)-Bradykinin | Lys-(Des-Arg9,Leu8)-Bradykinin is a bradykinin B1 receptor antagonist. |
M53241 | Lys-[Hyp3]-Bradykinin | Lys-[Hyp3]-Bradykinin a Bradykinin agonist. |
M53240 | Bradykinin (1-3) | Bradykinin (1-3) is a 3-amino acid residue peptide. |
M53239 | Retrobradykinin | Retrobradykinin has the reverse sequence of Bradykinin. |
M53238 | B 9430 | B 9430 is a potent bradykinin B1/B2 receptor antagonist. |
M53237 | R715 | R715 is a selective bradykinin B1 receptor antagonist. |
M45242 | Deucrictibant | Deucrictibant is a novel, potent, orally active small molecule bradykinin B2 receptor antagonist. |
M41788 | NPC-567 | NPC-567 is a bradykinin B2 receptor antagonist. |
M41787 | MEN 11270 | MEN 11270, a cyclic decapeptide, is a B2 kinin receptor antagonist. |
M41786 | Lys-Bradykinin | Lys-Bradykinin, a kind of kallidin and bradykinin receptor ligand, can be generated by kininogen protein through enzymatic cleavage by the protease kallikrein. |
M30763 | Fasitibant free base | Fasitibant (free base) is a potent, selective, high affinity, and long-lasting nonpeptide bradykinin B2 (BK2) receptor antagonist. Fasitibant (free base) has proinflammatory effects and can be used for the research of osteoarthritis and rheumatoid arthritis. |
M30761 | Fasitibant chloride hydrochloride | Fasitibant chloride hydrochloride (MEN16132) is a potent, selective, high affinity, and long-lasting nonpeptide bradykinin B2 (BK2) receptor antagonist. Fasitibant chloride hydrochloride has proinflammatory effects and can be used for the research of osteoarthritis and rheumatoid arthritis. |
M27862 | Fasitibant chloride | Fasitibant chloride (MEN16132 free base) is a potent and selective nonpeptide bradykinin B2 receptor (B2R) antagonist. Fasitibant chloride reduces joint pain and diminishes joint oedema in Carrageenan-induced arthritis rat model. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.